A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders.

Researchers gave zuclopenthixol pills or placebo to adults with intellectual disability living in a hospital.

The trial lasted 12 weeks. Staff and doctors did not know who got the real drug.

They tracked how often serious behavior problems happened.

The adults who took zuclopenthixol had fewer behavior problems than the placebo group.

Side effects were mild.

Hattier et al. (2011) looked at every antipsychotic trial for people with ID. They found most studies, like this one, are small and use different rulers to score behavior.

Strydom et al. (2020) tried PBS instead of pills for adults with both ID and autism. After 12 months the PBS group looked the same as usual care. The pill study worked; the PBS study did not. The difference may be that Strydom’s group also had autism, which can make drug and behavior results harder to read.

Mazonson et al. (2018) added manager coaching to PBS in adult homes and saw medium drops in problem behavior. Their mix of staff training plus light medication mirrors the calm seen here with pills alone, hinting that either route can help if the setting sticks to it.

You now have a 1992 signal that zuclopenthixol can cut challenging behavior in pure ID adults. Pair this with newer data showing PBS coaching also works. If you serve adults with ID only and medication is on the table, zuclopenthixol is worth a data-driven trial. Track behavior daily and watch for drowsiness or weight change. If the person also has autism, start with behavior supports first—the pill evidence is thinner.